GNBT PPS Set to Rocket on US Legalization of Industrial Hemp in Pending Passage of 2018 Farm Act

New York, NY -- November 28, 2018 -- InvestorsHub NewsWire -- Generex Biotechnology (GNBT) is long-term biotech player that has mounted a recent comeback under new leadership. The company has clinically trialed pharmaceutical intellectual property (IP) in house and new leadership is on an acquisition spree expanding the portfolio. GNBT is differentiating itself from other biotech companies by also building its own distribution network. The company has already acquired a small network of pharmacies and clinics with more in the pipeline. So unlike most biotech’s, GNBT will have revenue while continuing to develop and trial new pharmaceuticals, not to mention having their own network for launching new pharmaceuticals. All of this has taken the GNBT stock price in recent weeks from the $2 PPS range to flirting with a $20 PPS. But GNBT’s recent move into cannabidiol (CBD) extracts announced earlier this week may be the new leadership move that takes the GNBT stock price into the stratosphere.

Canadian cannabis stocks such as Canopy Growth (CGC) and Tilray (TLRY) saw their share prices skyrocket on the leadup to recreational marijuana legalization in Canada. As the cannabis market continues to mature, it now appears CBD derived products may be a bigger market opportunity than THC products. And the U.S. is on the verge of legalizing industrial hemp with hemp being a far larger source of CBD than marijuana. The U.S. market size dwarfs the Canadian market size and the legalization of hemp is likely to launch U.S. CBD stocks on fire surpassing the market caps of Canadian cannabis stocks. The new leadership at GNBT has strategically positioned the company to benefit from the what looks to be the now pending legalization of industrial hemp in the 2018 Farm Bill.

GNBT has been gaining experience for a longtime now in the cannabis pharmaceutical sector through a co-development initiative with Scientus Pharma, Inc., a Canadian cannabis pharmaceutical company financially backed by Canopy Growth. This week, GNBT made a more committed move into the U.S. CBD market announcing an agreement to produce therapeutic CBD Infused Water. GNBT entered into an agreement with one of the leading CBD beverage producers in the U.S., Puration, Inc. (PURA), which was recently courted by a U.S. Fortune 500 brand name beverage company. The deal comes with access to a patented cannabis extraction process licensed by PURA and owned by Kali, Inc. (KALY). The announcement included a mention that the agreement to produce the CBD Infused Water was part of an even bigger agreement in the works. Perhaps GNBT has PURA and KALY in its acquisition sites. In any case, a passage of the 2018 Farm Act that includes the legalization of industrial hemp has a very good possibility of the being the catalyst that takes the GNBT PPS to Canopy Growth and Tilray levels.

Learn more about Generex at http://www.generex.com/

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com